Tiago Girao

Tiago Girao serves as the Chief Financial Officer at Immunovant since April 2025, previously holding roles such as CFO in Residence at Roivant Sciences from December 2023 to April 2025 and Chief Financial Officer at Telavant for a brief period in late 2023. Girao was a Board Member at Landos Biopharma, Inc. during its acquisition by AbbVie, which concluded in May 2024. Girao's experience includes serving as CFO at Proteovant Therapeutics and Respivant Sciences, as well as various financial leadership positions at Cytori Therapeutics, NuVasive, and KPMG. Girao began a career in finance at Ernst & Young after earning a degree in Accounting from Universidade de Fortaleza.